---
layout: post
title: "1.4 hz - Rife Frequency"
description: "Scientific exploration of 1.4 Hz Rife frequency: bio-energetic resonance modeling for retinal pigment epithelial integrity and age-related macular degeneration."
subject: "1.4 hz - Rife Frequency"
apple-title: "1.4 hz - Rife Frequency"
app-name: "1.4 hz - Rife Frequency"
tweet-title: "1.4 hz - Rife Frequency"
tweet-description: "Scientific exploration of 1.4 Hz Rife frequency: bio-energetic resonance modeling for retinal pigment epithelial integrity and age-related macular degeneration."
date: 2023-07-12
keywords: "frequency benefits, Brain Beats Pro, Frequencies, brainwave entrainment, sound therapy, 1.4 hz, rife frequency, macular degeneration, retinal pigment epithelium, drusen, choroidal neovascularization, openfda aflibercept, pegcetacoplan, cafl frequencies, CAFL frequencies"
---

The **1.4 Hz Rife Frequency** is an infrasonic bio-resonance frequency listed in the Consolidated Annotated Frequency List (CAFL). It sits in the **infrasonic range** (below the 20 Hz lower limit of human hearing, so it is felt as vibration or heard only through amplitude modulation of an audible carrier) and is cataloged in the Consolidated Annotated Frequency List (CAFL) for **Macular degeneration 1**.

---

### 1. Microbiological & Pathological Profile

- **Age-Related Macular Degeneration (AMD) Pathobiology**: AMD is a complex neurodegenerative disorder of the central retina affecting the photoreceptors, retinal pigment epithelium (RPE), Bruch's membrane, and choriocapillaris. Early AMD is marked by confluent soft drusen and RPE pigmentary abnormalities. Geographic atrophy (late dry AMD) represents bilateral loss of RPE and overlying photoreceptors. Neovascular (wet) AMD involves pathological choroidal neovascularization (CNV) breaking through Bruch's membrane into the sub-retinal space, causing hemorrhage, exudation, and rapid central vision loss.
- **Ophthalmological Standard of Care & FDA Clearances**: Clinical standard of care for wet AMD relies strictly on intravitreal injections of FDA-approved anti-VEGF agents (Aflibercept/Eylea, BLA 125387; Ranibizumab/Lucentis, BLA 125156; Faricimab/Vabysmo, BLA 761235). Geographic atrophy is treated with FDA-approved complement cascade inhibitors (Pegcetacoplan/Syfovre, NDA 217171; Avacincaptad pegol/Izervay, NDA 217277). Nutritional prophylaxis follows the AREDS2 clinical trial guidelines. Sound frequencies do not suppress VEGF or clear drusen deposits.
- **Biophysical & Infrasonic Modeling**: The 1.4 Hz frequency corresponds to a period of $T \approx 0.714\text{ s}$, which closely correlates with normal human resting pulse rates (~84 bpm) and micro-pulsatile choroidal blood flow. In vibroacoustic modeling, 1.4 Hz is evaluated as a non-invasive circulatory entrainment rhythm to support ocular ocular perfusion and systemic relaxation.

---

### 2. Biophysical Mechanism of Action

```
+-----------------------------------------------------------------------------------------+
|                                1.4 Hz MECHANISM OF ACTION                               |
+-----------------------------------------------------------------------------------------+
                                             |
                      Acoustic Longitudinal Compression Wave (1.4 Hz)
                                             |
[Target Structure]               [Host Tissue]                    [Autonomic State]
|                                |                                |
Cyclic Mechanical Loading        Improved Local Perfusion         Relaxation Response
|                                |                                |
Possible Micro-Fatigue           Better Immune Access             Lower Stress Load
                                             |
                               Proposed Downstream Outcomes:
   * Mechanical loading of target structures (theoretical)
   * Perfusion and immune-access support
   * Relaxation-linked stress reduction
```

#### Resonance Breakdown
1. **Choroidal Vascular Pulsatility & Perfusion Kinetics**: Ocular blood flow is primarily choroidal (>85%), delivering vital nutrients and oxygen to the avascular foveal photoreceptors. Rhythmic 1.4 Hz acoustic or somatic stimulation aligns with resting arterial pulse harmonics, potentially supporting microvascular compliance and perfusion in the choriocapillaris without inducing mechanical intraocular pressure (IOP) spikes.
2. **Safety & Zero-Cavitation Transmission in Ocular Media**: For an infrasonic wave of $f = 1.4\text{ Hz}$, the acoustic wavelength in the vitreous humor ($c \approx 1532\text{ m/s}$) is $\lambda \approx 1094\text{ m}$. Because the eye diameter is $\approx 24\text{ mm}$, the mechanical wave exerts uniform hydrostatic pressure without spatial shear gradients, confirming the absence of mechanical traction on the neurosensory retina.

> [!NOTE]
> These mechanisms are theoretical models. No controlled clinical trial has shown that audible-frequency sound treats the conditions described here.

---

### 3. Harmonic Hierarchy & Resonance Tree

```
[0.175 Hz] <--- [0.35 Hz] <--- [0.7 Hz] <--- [1.4 Hz] ---> [2.8 Hz] ---> [4.2 Hz] ---> [5.6 Hz]
Grounding   Lymphatic   Perfusion   Master   Overtone 1   Overtone 2   Overtone 3
```

- **Fundamental ($f_0$)**: 1.4 Hz, the primary resonance driver for this preset.
- **Sub-Harmonic ($f_{-1} = 0.7\text{ Hz}$)**: Supports perfusion and relaxation.
- **Sub-Harmonic ($f_{-2} = 0.35\text{ Hz}$)**: Supports lymphatic flow and deep relaxation.
- **Harmonic ($2f_0 = 2.8\text{ Hz}$)**: Second-order overtone for mechanical loading.
- **Harmonic ($3f_0 = 4.2\text{ Hz}$)**: Third-order overtone for micro-streaming.

---

### 4. Practical Session Parameters

| Parameter | Recommended Specification | Research Objective |
| :--- | :--- | :--- |
| **Delivery Medium** | Amplitude-modulated audible carrier through headphones, or a tactile transducer | Even, low-distortion acoustic delivery |
| **Waveform Dynamic** | Pure sine wave with gentle 0.1 Hz amplitude modulation | Avoids sensory adaptation during extended sessions |
| **Exposure Schedule** | 20 to 30 minutes once daily for 10 to 14 days | Matches typical research session length |
| **Supportive Regimen** | Hydration, balanced nutrition, rest; evidence-based medical care where indicated | Supports recovery; does not replace standard medical care |

> **Interactive Sound Laboratory:** Experience the **1.4 Hz** frequency live on the **[Brain Beats Pro Pure Tone Generator](/pure-tone-generator.html)**, test multi-wave entrainment with the **[Binaural Beats Generator](/binaural-beats-generator.html)**, or cross-reference complementary targets in the **[Rife Frequencies CAFL Directory](/rife-frequencies-cafl-xref.html)**.
>
> **Medical Disclaimer:** The vibrational protocols discussed herein are intended for scientific modeling, psychoacoustic research, and complementary sound therapy. They do not constitute medical diagnosis, clinical advice, or treatment. Sudden distortion of straight lines (metamorphopsia), sudden onset of a dark spot in central vision, or rapid vision deterioration require urgent same-day ophthalmological evaluation. Always consult licensed healthcare practitioners for medical concerns.

---

### 5. Web Audio API Master Synthesizer

```javascript
/**
 * Rife1_4Synthesizer - Web Audio API Synthesis Engine for 1.4 Hz
 * 1.4 Hz is infrasonic, so it is rendered as amplitude modulation of a 200 Hz carrier.
 */
class Rife1_4Synthesizer {
  constructor() {
    this.audioCtx = null;
    this.carrier = null;
    this.subOctave = null;
    this.masterGain = null;
    this.isActive = false;
  }

  init() {
    const AudioCtx = window.AudioContext || window.webkitAudioContext;
    this.audioCtx = new AudioCtx();

    this.masterGain = this.audioCtx.createGain();
    this.masterGain.gain.setValueAtTime(0.0001, this.audioCtx.currentTime);
    this.masterGain.connect(this.audioCtx.destination);
  }

  start(durationMinutes = 30) {
    if (!this.audioCtx) this.init();
    if (this.isActive) return;

    const t = this.audioCtx.currentTime;

    // 1.4 Hz is below the hearing range: modulate a 200 Hz carrier at 1.4 Hz
    this.carrier = this.audioCtx.createOscillator();
    this.carrier.type = 'sine';
    this.carrier.frequency.setValueAtTime(200, t);

    // Low-frequency oscillator at 1.4 Hz drives the carrier amplitude
    this.subOctave = this.audioCtx.createOscillator();
    this.subOctave.type = 'sine';
    this.subOctave.frequency.setValueAtTime(1.4, t);

    const depth = this.audioCtx.createGain();
    depth.gain.setValueAtTime(0.5, t);
    const amp = this.audioCtx.createGain();
    amp.gain.setValueAtTime(0.5, t);

    this.subOctave.connect(depth);
    depth.connect(amp.gain);
    this.carrier.connect(amp);
    amp.connect(this.masterGain);

    // Smooth attack ramp
    this.masterGain.gain.exponentialRampToValueAtTime(0.3, t + 3);

    this.carrier.start(t);
    this.subOctave.start(t);
    this.isActive = true;

    // Scheduled session shutdown
    const stopTime = t + (durationMinutes * 60);
    this.masterGain.gain.setValueAtTime(0.3, stopTime - 3);
    this.masterGain.gain.exponentialRampToValueAtTime(0.0001, stopTime);
    this.carrier.stop(stopTime);
    this.subOctave.stop(stopTime);

    this.carrier.onended = () => {
      this.isActive = false;
    };
  }

  stop() {
    if (!this.isActive || !this.audioCtx) return;
    const t = this.audioCtx.currentTime;
    this.masterGain.gain.linearRampToValueAtTime(0.0001, t + 1);
    setTimeout(() => {
      if (this.carrier) this.carrier.stop();
      if (this.subOctave) this.subOctave.stop();
      this.isActive = false;
    }, 1000);
  }
}

// Example usage:
// const session = new Rife1_4Synthesizer();
// document.getElementById('btnStart').addEventListener('click', () => session.start(30));
```

---

### 6. Summary & Academic Citations

The **1.4 Hz Rife Frequency** is a CAFL catalog entry presented here as a psychoacoustic and biophysical modeling reference, not as a treatment.

1. Mitchell, P., et al. (2018). Age-related macular degeneration. The Lancet, 392(10153), 1147-1159.
2. Brown, D. M., et al. (2006). Ranibizumab versus verteporfin for neovascular age-related macular degeneration. New England Journal of Medicine, 355(14), 1432-1444.
3. Age-Related Eye Disease Study 2 (AREDS2) Research Group. (2013). Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the AREDS2 randomized clinical trial. JAMA, 309(19), 2005-2015.
4. U.S. Food and Drug Administration. (2023). FDA Approves Izervay (avacincaptad pegol intravitreal solution) for the Treatment of Geographic Atrophy. FDA Reference NDA 217277.

---

<div align="center">
<sub>&copy; Brain Beats Pro. Written content and research documentation are licensed under <a href="/licenses.html" rel="license">CC BY 4.0</a>. Web Audio synthesis mechanics and source code are copyleft protected under <a href="/licenses.html">GNU AGPLv3</a>.</sub>
</div>
